Article Sidebar
Published:
Aug 10, 2022Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Comparison of adalimumab and secukinumab with respect to short-term efficacy and recurrence in moderate-tosevere psoriasis patients
Abstract
Purpose: To compare the short-term efficacy and recurrence of moderate-to-severe psoriasis patients through adalimumab and secukinumab.
Methods: A total of 180 patients treated in 970 Hospital of the PLA Joint Logistics Support Force from April 2019 to November 2021 were enrolled in this study. They were assigned to groups A (100 cases treated with secukinumab) and B (80 patients treated with adalimumab). Before and after treatment, the IL-23, TNF-α and 25 (OH) D levels, psoriasis area and severity index (PASI), physician global assessment (PGA), dermatology life quality index (DLQI), compliance with treatment, treatment effectiveness, incidence of adverse reactions, and short-term recurrence were assessed.
Results: After treatment, the TNF-α and IL-23 levels decreased in group A, while the 25 (OH) D level increased (p < 0.05). In comparison to group B, PASI, PGA and DLQI scores in group A were lower (p < 0.05). Compliance in group A was lower (p = 0.002), while total treatment effectiveness was higher (p < 0.001). The incidence of adverse reactions (p =0.004) and frequency of short-term recurrence (p = 0.005) in group A were lower.
Conclusion: The short-term efficacy of secukinumab in moderate-to-severe psoriasis patients is higher
than that of adalimumab, while recurrence is lower. Thus, secukinumab shows greater benefits than adalimumab for the treatment psoriasis.
